Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan Phase 3 Trial in Generalized Myasthenia Gravis (AChR-positive) – Japan
jRCT2080225130Phase 3Completed
- Start
- Mar 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
01
Overview
Phase 3 trial of zilucoplan in myasthenia gravis (MG). Primary endpoint: Primary safety and tolerability. Started Mar 2020; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2080225130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225130.